Additionally, the GLP-1 receptor agonist semaglutide has been shown to alleviate symptoms of heart failure and enhance exercise capacity in patients with obesity-related heart failure and HFpEF, regardless of their diabetes status. Here, GLP1R is linked to heart failure.